Metabolex, Inc.

Home > Pipeline > MBX-102

Novel Uricosuric Treatment for Patients with Gout

MBX-102 is a novel oral small molecule uricosuric agent that is an attractive new therapy for the treatment of gout. MBX-102 not only controls hyperuricemia, leading to reduced risk of flares and dissolution of tophi, but also addresses other aspects of metabolic syndrome.

Clinical Development

MBX-102 has demonstrated robust uric acid lowering in normal subjects and patients with type 2 diabetes with once daily dosing. MBX-102 was initially being developed for type 2 diabetes, and has completed eight Phase 1 and four Phase 2 studies. During this development program, Metabolex discovered that MBX-102 is an effective uricosuric agent with unique properties, and is repurposing the drug to treat gout. MBX-102’s excellent safety and tolerability have been demonstrated in more than 870 patients (>190 patient-years) treated with doses of up to 600 mg for 6 months.

Impressive Profile

MBX-102 demonstrates robust, dose-dependent uricosuric activity with once daily dosing, with no loss of activity in patients with mild-to-moderate renal insufficiency or in patients on concomitant aspirin therapy. The uricosuric effect is achieved without increasing urine acidity, thereby not increasing the risk of urolithiasis, and without any effect on kidney function. Additional benefits of MBX-102 include significant improvements in insulin sensitivity, as well as reductions in serum glucose, triglycerides, and markers of inflammation. This wide spectrum of beneficial effects makes MBX-102 an attractive new therapy for the treatment of gout that also addresses other aspects of metabolic syndrome commonly seen in patients with hyperuricemia and gout.